Technical Analysis for ASRT - Assertio Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Death Cross | Bearish | 0.00% | |
| Fell Below 20 DMA | Bearish | 0.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Crossed Above 20 DMA | Bullish | -2.55% | |
| Volume Surge | Other | -2.55% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 17 hours ago |
| Down 5% | about 21 hours ago |
| Down 3% | about 21 hours ago |
| Down 2 % | about 22 hours ago |
| Down 1% | about 22 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/11/2024
Assertio Therapeutics, Inc. Description
Assertio Therapeutics, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), Cambia (diclofenac potassium for oral solution), Xartemis XR and Zipsor (diclofenac potassium). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia (PHN). Its Cambia (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pain Organ Systems Organic Compounds Chemical Compounds Opioids Analgesics Potassium Acute Pain Neuropathic Pain Migraine Peripheral Neuropathy Amino Acids Diabetic Peripheral Neuropathy Treatment Of Migraine Postherpetic Neuralgia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.798 |
| 52 Week Low | 0.7324 |
| Average Volume | 624,240 |
| 200-Day Moving Average | 1.09 |
| 50-Day Moving Average | 1.09 |
| 20-Day Moving Average | 0.97 |
| 10-Day Moving Average | 0.89 |
| Average True Range | 0.08 |
| RSI (14) | 46.52 |
| ADX | 41.91 |
| +DI | 22.82 |
| -DI | 27.96 |
| Chandelier Exit (Long, 3 ATRs) | 0.91 |
| Chandelier Exit (Short, 3 ATRs) | 1.03 |
| Upper Bollinger Bands | 1.15 |
| Lower Bollinger Band | 0.78 |
| Percent B (%b) | 0.45 |
| BandWidth | 37.96 |
| MACD Line | -0.06 |
| MACD Signal Line | -0.06 |
| MACD Histogram | 0.0034 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.06 | ||||
| Resistance 3 (R3) | 1.06 | 1.03 | 1.04 | ||
| Resistance 2 (R2) | 1.03 | 1.00 | 1.03 | 1.03 | |
| Resistance 1 (R1) | 0.99 | 0.98 | 0.97 | 0.99 | 1.03 |
| Pivot Point | 0.96 | 0.96 | 0.95 | 0.96 | 0.96 |
| Support 1 (S1) | 0.92 | 0.93 | 0.90 | 0.91 | 0.87 |
| Support 2 (S2) | 0.89 | 0.91 | 0.88 | 0.87 | |
| Support 3 (S3) | 0.85 | 0.89 | 0.86 | ||
| Support 4 (S4) | 0.84 |
